|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
StreetInsider.com
May 21
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/GenVec+%28GNVC%29+CEO+Fischer+to+Step+Down%3B+Successor+Named/7456674.html for the full story.
Benzinga
May 21
Comment
GenVec, Inc. (NASDAQ: GNVC) today announced that effective May 23, 2012 Cynthia Collins has been appointed as President and Chief Executive Officer. In addition, Ms. Collins is expected to be appointed to the Board of Directors of GenVec....
PR Newswire
May 10
Comment
GAITHERSBURG, Md., May 10, 2012 /PRNewswire/ -- Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the first quarter ended March 31, 2012. GenVec reported a net loss of $3.2 million, or $0.25 per share, compared with a net loss of $2.2
GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
PR Newswire
May 3
Comment
GAITHERSBURG, Md., May 3, 2012 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) will report financial results for the first quarter ended March 31, 2012 on Thursday, May 10, 2012, before the U.S. financial markets open. The announcement will be followed
StreetInsider.com
May 3
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/GenVec+%28GNVC%29+Gets+%24590K+SBIR+Grant+from+NIAID+of+NIH/7397967.html for the full story.
PR Newswire
May 3
Comment
GAITHERSBURG, Md., May 3, 2012 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of
PR Newswire
Apr 6
Comment
GAITHERSBURG, Md., April 6, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) announced publication of research on GenVec's new vaccine vectors. These vectors circumvent neutralizing antibodies in order to generate the desired immunologic response.
Business Wire
Apr 3
Comment
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of investors who purchased GenVec, Inc. (“GenVec” or the “Company”) (Nasdaq: GNVC) stock
Benzinga
Mar 26
Comment
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R43AI100467 to support the company's malaria vaccine...
Marketwire
Feb 3
Comment
STEVENSON, MD -- (Marketwire) -- 02/03/12 -- The law firm of Brower Piven, A Professional Corporation, has filed a class action suit in the United States District Court for the District of Maryland on behalf of all investors who purchased or
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
